COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice

Hum Genomics. 2020 Jun 4;14(1):20. doi: 10.1186/s40246-020-00272-6.

Abstract

Coronavirus disease 2019 (COVID-19) is a declared pandemic that is spreading all over the world at a dreadfully fast rate. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen of COVID-19, infects the human body using angiotensin-converting enzyme 2 (ACE2) as a receptor identical to the severe acute respiratory syndrome (SARS) pandemic that occurred in 2002-2003. SARS-CoV-2 has a higher binding affinity to human ACE2 than to that of other species. Animal models that mimic the human disease are highly essential to develop therapeutics and vaccines against COVID-19. Here, we review transgenic mice that express human ACE2 in the airway and other epithelia and have shown to develop a rapidly lethal infection after intranasal inoculation with SARS-CoV, the pathogen of SARS. This literature review aims to present the importance of utilizing the human ACE2 transgenic mouse model to better understand the pathogenesis of COVID-19 and develop both therapeutics and vaccines.

Keywords: Angiotensin-converting enzyme 2 (ACE2); COVID-19; Coronavirus; SARS-CoV-2; Transgenic mouse.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Animals
  • Betacoronavirus / metabolism*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / pathology*
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Pandemics
  • Peptidyl-Dipeptidase A / genetics*
  • Peptidyl-Dipeptidase A / metabolism*
  • Pneumonia, Viral / pathology*
  • Promoter Regions, Genetic / genetics
  • Protein Binding / physiology
  • Receptors, Virus / genetics
  • Receptors, Virus / metabolism
  • SARS-CoV-2

Substances

  • Receptors, Virus
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2